AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11784875 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Number of subjects: 1207
Study 9713935 — intervention group
Group type: EXPERIMENTAL
Intervention: diphtheria‐tetanus‐acellular pertussis (dTap) vaccine
Number of subjects: 235
Study 9713935 — intervention group
Group type: COMPARATOR
Intervention: diphtheria‐tetanus (dT) vaccine
Number of subjects: 235
Study 8064352 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant velocity trajectory
Number of subjects: 0
Study 8064352 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable velocity trajectory
Number of subjects: 0
Study 2840652 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (doses adjusted to each individual case)
Number of subjects: 10
Study 30033035 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-IORT
Number of subjects: 34
Study 30033035 — intervention group
Group type: COMPARATOR
Intervention: WBI-DIBH
Number of subjects: 34
Study 30033035 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT
Number of subjects: 34
Study 28495811 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education programme
Number of subjects: 180
Study 28495811 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 180
Study 25556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy (VT)
Number of subjects: 41
Study 25556965 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculotomy (T)
Number of subjects: 41
Study 22975439 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Clinical Event Committee (CEC) adjudication
Number of subjects: 2292
Study 22975439 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonization recommendations applied to the overall RAC population
Number of subjects: 2292
Study 20677606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% lignocaine 75 mg
Number of subjects: 52
Study 20677606 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 12.5 mg
Number of subjects: 52
Study 17571086 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol fixed combination (BTFC)
Number of subjects: 28
Study 17571086 — intervention group
Group type: COMPARATOR
Intervention: Unfixed combination of brimonidine and timolol
Number of subjects: 28
Study 16648043 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (20 mg/kg bodyweight)
Number of subjects: 322
Study 16648043 — intervention group
Group type: COMPARATOR
Intervention: White light (conventional microsurgery)
Number of subjects: 322
Study 12954243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic flucloxacillin
Number of subjects: 193
Study 12954243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 11030854 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Choices intervention
Number of subjects: 345
Study 8780294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 3 microgram/kg induction in Group M (ventilated via mask)
Number of subjects: 40
Study 8780294 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 3 microgram/kg induction in Group E (ventilated via endotracheal tube)
Number of subjects: 40
Study 1623029 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure plus sensation (experimental)
Number of subjects: 22
Study 1623029 — intervention group
Group type: COMPARATOR
Intervention: Procedure (control)
Number of subjects: 22
Study 6382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg twice a day
Number of subjects: 370
Study 6382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg twice a day
Number of subjects: 370
Study 6382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 370
Study 6382004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 6382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine in smokers
Number of subjects: 370
Study 6382004 — intervention group
Group type: COMPARATOR
Intervention: Placebo in smokers
Number of subjects: 370
Study 30001704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness for Bipolar 2.0
Number of subjects: 300
Study 30001704 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation for Bipolar
Number of subjects: 300
Study 26804670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitors (5-ARIs)
Number of subjects: 6537
Study 26804670 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blockers
Number of subjects: 6537
Study 24607046 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02, one spray per nostril twice daily (total daily doses of azelastine hydrochloride and FP were 548 mcg and 200 mcg, respectively)
Number of subjects: 612
Study 24607046 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 2 sprays per nostril once daily (total daily dose 200 mcg)
Number of subjects: 612
Study 24607046 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 612
Study 24607046 — intervention group
Group type: COMPARATOR
Intervention: MP29-02 and FP
Number of subjects: 612
Study 22396230 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) using cloth covered cooling gel packs for 72 hours
Number of subjects: 0
Study 22396230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 0
Study 20178792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue injections (n = 36)
Number of subjects: 77
Study 20178792 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 41)
Number of subjects: 77
Study 18566461 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 484
Study 18566461 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study 15777971 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 105
Study 12804929 — intervention group
Group type: EXPERIMENTAL
Intervention: Single chamber pacemakers
Number of subjects: 307
Study 12804929 — intervention group
Group type: COMPARATOR
Intervention: Dual chamber pacemakers
Number of subjects: 307
Study 12804929 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation
Number of subjects: 307
Study 12804929 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 307
Study 12804929 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 307
Study 12804929 — intervention group
Group type: EXPERIMENTAL
Intervention: History of ischaemic heart disease
Number of subjects: 307
Study 12804929 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of pacing
Number of subjects: 307
Study 10745303 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 20
Study 10745303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8701480 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation therapy with magnesium sulfate
Number of subjects: 20
Study 8701480 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation therapy with salbutamol sulfate
Number of subjects: 20
Study 1512329 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 1330
Study 6859073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (large doses)
Number of subjects: 0
Study 6859073 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term nitrate therapy
Number of subjects: 0
Study 6859073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31836583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised surfactant
Number of subjects: 32
Study 31836583 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 32
Study 30200925 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for African American children)
Number of subjects: 0
Study 30200925 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for white children)
Number of subjects: 0
Study 30200925 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for African American parents)
Number of subjects: 0
Study 30200925 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for white parents)
Number of subjects: 0
Study 26910903 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided laser interstitial thermal therapy (laser ablation)
Number of subjects: 20
Study 24744317 — intervention group
Group type: EXPERIMENTAL
Intervention: FA plus 30 mg of iron (IFA)
Number of subjects: 834
Study 24744317 — intervention group
Group type: EXPERIMENTAL
Intervention: FA, iron, plus 13 additional micronutrients (MM)
Number of subjects: 834
Study 24744317 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) (control)
Number of subjects: 834
Study 24744317 — intervention group
Group type: EXPERIMENTAL
Intervention: FA plus 30 mg of iron (IFA) and FA, iron, plus 13 additional micronutrients (MM)
Number of subjects: 834
Study 22185768 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Movement Therapy (PMT) three times a week for four weeks
Number of subjects: 101
Study 22185768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PMT)
Number of subjects: 101
Study 20671078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Ulcer Classification education tool (PUCLAS)
Number of subjects: 1217
Study 20671078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1217
Study 17492901 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities for chronic pelvic pain
Number of subjects: 0
Study 15901015 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching with saliva contamination
Number of subjects: 18
Study 15901015 — intervention group
Group type: EXPERIMENTAL
Intervention: NRC etching with saliva contamination
Number of subjects: 18
Study 15901015 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid etching without saliva contamination
Number of subjects: 18
Study 15901015 — intervention group
Group type: COMPARATOR
Intervention: NRC etching without saliva contamination
Number of subjects: 18
Study 12501064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 119
Study 12501064 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 119
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFil superior without conditioner
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFil superior with conditioner
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC with conditioner
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFil superior with and without conditioner
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Fil
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer cements (C-GIC)
Number of subjects: 96
Study 11317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac-Fil quick
Number of subjects: 96
Study 8973996 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 16
Study 8973996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1601764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1g bd
Number of subjects: 276
Study 1601764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2g bd
Number of subjects: 276
Study 4061020 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group I (children under 10)
Number of subjects: 40
Study 4061020 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group II (children over 10)
Number of subjects: 40
Study 4061020 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group III (children over 10)
Number of subjects: 40
Study 4061020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium and thiopentone during intravenous induction in group III (children over 10)
Number of subjects: 40
Study 30843873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous (t.c.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60
Study 30843873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60
Study 30843873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60
Study 30843873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early innate gene signature
Number of subjects: 60
Study 30843873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine genes and serum level of CXCL10
Number of subjects: 60
Study 30538429 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of roflumilast (0.25, 0.375, and 0.5 mg)
Number of subjects: 12
Study 30538429 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of roflumilast (0.375 mg once daily for 11 days)
Number of subjects: 12
Study 30538429 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation (monitoring, physical examination, vital sign tests, clinical laboratory tests)
Number of subjects: 12
Study 27813422 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501 (40 mg subcutaneous dose)
Number of subjects: 327
Study 27813422 — intervention group
Group type: COMPARATOR
Intervention: US-approved Humira (40 mg subcutaneous dose)
Number of subjects: 327
Study 27813422 — intervention group
Group type: COMPARATOR
Intervention: EU-approved Humira (40 mg subcutaneous dose)
Number of subjects: 327
Study 27813422 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501, US-approved Humira, EU-approved Humira
Number of subjects: 327
Study 25227627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene plus psychosocial support
Number of subjects: 0
Study 25227627 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial support alone
Number of subjects: 0
Study 23190528 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality models for planning tumor resection
Number of subjects: 60
Study 19907167 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in combination with rt-PA thrombolysis
Number of subjects: 800
Study 19907167 — intervention group
Group type: COMPARATOR
Intervention: rt-PA thrombolysis alone
Number of subjects: 800
Study 17691590 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with orange juice (enhancer)
Number of subjects: 32
Study 17691590 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with food
Number of subjects: 32
Study 17691590 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered during fasting
Number of subjects: 32
Study 17691590 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III)‐hydroxide polymaltose complex (IPC) administered with black tea (inhibitor)
Number of subjects: 32
Study 16254756 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity intervention
Number of subjects: 134
Study 16254756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 11908739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) as a single agent for three months
Number of subjects: 58
Study 11908739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine during induction
Number of subjects: 58
Study 10440409 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0
Study 10440409 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual or triple cyclosporine A immunosuppressive therapy
Number of subjects: 0
Study 7540478 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (2 IU/M2) continued until variant GH production from the placenta was evident.
Number of subjects: 1
Study 7540478 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (2 IU/M2) during pregnancy.
Number of subjects: 1
Study 2129647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms b.d.
Number of subjects: 103
Study 2129647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms b.d.
Number of subjects: 103
Study 2129647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31425040 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized Ankle Stretcher (MAS) technology
Number of subjects: 16
Study 31425040 — intervention group
Group type: COMPARATOR
Intervention: Stretching board (Control)
Number of subjects: 16
Study 29261736 — intervention group
Group type: COMPARATOR
Intervention: Oral vancomycin (250mg every 6 h for 10-14 days)
Number of subjects: 19
Study 29261736 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT‐FURM (Fecal microbiota transplant)
Number of subjects: 19
Study 25223524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotarem(®)
Number of subjects: 41
Study 25223524 — intervention group
Group type: COMPARATOR
Intervention: MultiHance(®)
Number of subjects: 41
Study 24028842 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a medical clown during intravenous catheter insertion
Number of subjects: 0
Study 24028842 — intervention group
Group type: COMPARATOR
Intervention: Absence of a medical clown during intravenous catheter insertion
Number of subjects: 0
Study 21753188 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide 10 mg/day
Number of subjects: 205
Study 21753188 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide 5 mg/day
Number of subjects: 205
Study 21753188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 205
Study 21753188 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide (combined groups)
Number of subjects: 205
Study 19013718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 18
Study 19013718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50mg QID
Number of subjects: 18
Study 19013718 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 18
Study 16256435 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-S and PPD-B dual testing
Number of subjects: 17530
Study 16256435 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-B with induration <10mm
Number of subjects: 17530
Study 16256435 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tuberculous mycobacteria infection
Number of subjects: 17530
Study 15290114 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Gated SPECT (QGS), Emory Cardiac Toolbox (ECT), Stanford University (SU-Segami) Medical School algorithm
Number of subjects: 31
Study 11726828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 5599
Study 11726828 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 5599
Study 9143888 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect laser treatment (scatter photocoagulation)
Number of subjects: 0
Study 9143888 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study 8191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (15 mg)
Number of subjects: 20
Study 8191269 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (1.5 mg)
Number of subjects: 20
Study 8191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 15
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopirin (SQUIBB)
Number of subjects: 15
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensiomin (EGIS)
Number of subjects: 15
Study 3075406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine + Lopirin
Number of subjects: 15
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine + Tensiomin
Number of subjects: 15
Study 3075406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine + Placebo
Number of subjects: 15
Study 31776882 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Peer Social Intervention (PPSI) for play, interaction, or conversation over 6 months
Number of subjects: 65
Study 31776882 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Peer Social Intervention (PPSI)
Number of subjects: 65
Study 31776882 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted-treatment-as-usual control group
Number of subjects: 65
Study 30112398 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital workflow (monolithic zirconia crown)
Number of subjects: 50
Study 30112398 — intervention group
Group type: COMPARATOR
Intervention: Analog workflow (metal-ceramic crown)
Number of subjects: 50
Study 27405049 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care skills training with solution-focused counselling
Number of subjects: 72
Study 27405049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 25572415 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 CPD
Number of subjects: 0
Study 25572415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 CPD
Number of subjects: 0
Study 25572415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 CPD
Number of subjects: 0
Study 25572415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 CPD
Number of subjects: 0
Study 25572415 — intervention group
Group type: COMPARATOR
Intervention: 19-25 CPD
Number of subjects: 0
Study 22963932 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vortioxetine
Number of subjects: 600
Study 22963932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 20689757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and methotrexate (CM)
Number of subjects: 108
Study 20689757 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC)
Number of subjects: 108